Key result
ST-segment elevation in lead aVR is linked to ~123% higher in-hospital mortality in cardiac arrest survivors.
Why the study?
Although ST-segment elevation in lead aVR indicates global myocardial ischaemia and correlates with increased mortality in acute coronary syndrome, its prevalence and prognostic significance in cardiac arrest patients is unknown.
Does ST-segment elevation in lead aVR predict in-hospital mortality and poor neurologic outcome in patients who achieve return of spontaneous circulation after cardiac arrest?
Cohort (n=443)
Does ST-segment elevation in lead aVR predict in-hospital mortality and poor neurologic outcome in patients who achieve return of spontaneous circulation after cardiac arrest?
ST-segment elevation in lead aVR is present in nearly 20% of cardiac arrest survivors and serves as an independent predictor of in-hospital mortality.
STE-aVR associated with higher in-hospital mortality post-arrest; leaves open its added value for risk stratification or neurologic prognostication.
AIMS: In acute coronary syndrome, ST-segment elevation in lead aVR (STE-aVR) indicates global myocardial ischaemia, often related to multivessel or severe left main disease, and correlates with increased mortality. The prevalence and prognostic significance of STE-aVR in cardiac arrest (CA) patients is unknown. METHODS AND RESULTS: We identified patients (≥18 years) with CA between 2011 and 2022 who achieved return of spontaneous circulation (ROSC). The first electrocardiogram post-ROSC was assessed for STE-aVR, defined as ≥1 mm ST-segment elevation at the J point, measured by two trained assessors. Multivariable logistic regression was used to analyse the association between STE-aVR and outcomes (in-hospital mortality and poor neurologic outcome), adjusted for patient and arrest characteristics. Including 443 CA patients, the median (interquartile range) age was 61 years (50-72 years), with 60.5% (n = 268) male, 65.7% (n = 291) presenting with out-of-hospital CA (OHCA), and 29.8% (n = 132) with shockable rhythms. ST-segment elevation in lead aVR was observed in 18.3% (n = 81) of patients. Those with STE-aVR were more likely to present with OHCA and less likely to have a shockable rhythm (both, P < 0.05). ST-segment elevation in lead aVR was associated with higher in-hospital mortality (86.4% vs. 65.8%, P < 0.001) and poor neurologic outcomes (90.1% vs. 72.9%, P = 0.001). After multivariable adjustment, STE-aVR remained associated with higher in-hospital mortality [odds ratio (OR) 2.23; 95% confidence interval (CI): 1.02-4.84, P = 0.04], but not a poor neurologic outcome (OR 2.12; 95% CI: 0.90-4.98, P = 0.09). CONCLUSION: ST-segment elevation in lead aVR was present in one in five CA survivors and was independently associated with higher in-hospital mortality.
No takes yet. Share an insight, caveat, or question.
Banna et al. (2025) conducted a cohort in Cardiac arrest (n=443). ST-segment elevation in lead aVR (STE-aVR) vs. No ST-segment elevation in lead aVR was evaluated on In-hospital mortality (OR 2.23, 95% CI 1.02-4.84, p=0.04). ST-segment elevation in lead aVR was independently associated with higher in-hospital mortality among cardiac arrest survivors (OR 2.23; 95% CI 1.02-4.84; P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: